These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34748189)

  • 1. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M; Brand E
    Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of switching from agalsidase-α to agalsidase-β on biomarkers, renal and cardiac parameters, and disease severity in fabry disease forming neutralizing antidrug antibodies: a case report.
    Shima H; Tsukimura T; Shiga T; Togawa T; Sakuraba H; Doi T; Ikeda Y; Okamoto T; Yoshikawa Y; Kimura T; Iwase T; Inoue T; Tashiro M; Okada K; Minakuchi J
    CEN Case Rep; 2024 Aug; 13(4):290-296. PubMed ID: 38135868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
    Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
    Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
    Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
    Hughes D; Gonzalez D; Maegawa G; Bernat JA; Holida M; Giraldo P; Atta MG; Chertkoff R; Alon S; Almon EB; Rocco R; Goker-Alpan O
    Genet Med; 2023 Dec; 25(12):100968. PubMed ID: 37634127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
    Wallace EL; Goker-Alpan O; Wilcox WR; Holida M; Bernat J; Longo N; Linhart A; Hughes DA; Hopkin RJ; Tøndel C; Langeveld M; Giraldo P; Pisani A; Germain DP; Mehta A; Deegan PB; Molnar MJ; Ortiz D; Jovanovic A; Muriello M; Barshop BA; Kimonis V; Vujkovac B; Nowak A; Geberhiwot T; Kantola I; Knoll J; Waldek S; Nedd K; Karaa A; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Sakov A; Warnock DG
    J Med Genet; 2024 May; 61(6):520-530. PubMed ID: 37940383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data.
    Feriozzi S; Chimenti C; Reisin RC
    Drug Des Devel Ther; 2024; 18():1083-1101. PubMed ID: 38585254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
    Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E
    Front Immunol; 2021; 12():789142. PubMed ID: 34917096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease.
    Deng M; Zhou H; Liang Z; Li Z; Wang Y; Guo W; Zhao AY; Li F; Mu Y; Zhao AZ
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
    Linhart A; Dostálová G; Nicholls K; West ML; Tøndel C; Jovanovic A; Giraldo P; Vujkovac B; Geberhiwot T; Brill-Almon E; Alon S; Chertkoff R; Rocco R; Hughes D
    Orphanet J Rare Dis; 2023 Oct; 18(1):332. PubMed ID: 37865771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.
    Ferrari G; Kisinovsky I; Reisin R; Rozenfeld P; Neumann P; Finn V; Marchesoni C; Quieto P;
    Medicina (B Aires); 2024; 84(3):516-525. PubMed ID: 38907966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
    Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
    Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.
    Frustaci A; Verardo R; Galea N; Alfarano M; Magnocavallo M; Marchitelli L; Sansone L; Belli M; Cristina M; Frustaci E; Russo MA; Chimenti C
    J Am Heart Assoc; 2024 Apr; 13(8):e032734. PubMed ID: 38563373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
    Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
    Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy.
    Kubota T; Tsukimura T; Shiga T; Togawa T; Sakuraba H
    CEN Case Rep; 2023 May; 12(2):171-175. PubMed ID: 36205882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
    Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
    Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
    Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
    F1000Res; 2021; 10():841. PubMed ID: 34745562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.